Novo Nordisk and Eli Lilly have broken ahead of the pack , locking up their leadership positions in weight loss treatment for several years to come, but the creation of this lucrative market has already attracted rivals that want a piece of the action. With more than two-thirds of U.S. adults having obesity or overweight, there is a huge unmet need that will allow several drugs to be commercially successful.
are expected to lead to greater efficacy, with a higher proportion of responders and an improved quality of treatment effect based on positive changes in lipids, blood pressure, glycemic control and other outcome parameters," Morgan Stanley analyst Mark Purcell wrote in a recent research note. Zealand Pharma has an amylin analogue that could be very competitive Purcell said.